TrialThe oncologist2026

EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer.

Albert Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.